title: Phase II trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer.
abstract: OBJECTIVE
  The objective of this study was to evaluate the efficacy and safety of Endostar combined with concurrent chemoradiotherapy (CCRT) in patients with stage III non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  Patients with unresectable stage III NSCLC were treated with Endostar (7.5mg/m(2)/d) for 7days at weeks 1, 3, 5, and 7, while two cycles of docetaxel (65mg/m(2)) and cisplatin (65mg/m(2)) were administered on days 8 and 36, with concurrent thoracic radiation to a dose of 60-66Gy. Primary end points were short-term efficacy and treatment-related toxicity.
  
  
  RESULTS
  Fifty patients were enrolled into the study, and 48 were assessable. Of the 48 patients, 83% had stage IIIB and 65% had N3 disease. Median follow-up was 25.0months. Overall response rate was 77%. The estimated median progression-free survival (PFS) was 9.9months, and the estimated median overall survival (OS) was 24.0months. The 1-, 2-, and 3-year local control rates were 75%, 67%, and 51%, PFS rates were 48%, 27%, and 16%, and OS rates were 81%, 50%, and 30%, respectively. All toxicities were tolerable with proper treatment.
  
  
  CONCLUSIONS
  The combination of Endostar with CCRT for locally advanced NSCLC patients was feasible and showed promising survival and local control rates.
authors.affiliation: Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China. Electronic address: baoyong@sysucc.org.cn.
authors.forename: Yong
authors.initials: Y
authors.lastname: Bao
authors.affiliation: Department of Radiation Oncology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
authors.forename: Fang
authors.initials: F
authors.lastname: Peng
authors.affiliation: Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
authors.forename: Qi-Chao
authors.initials: QC
authors.lastname: Zhou
authors.affiliation: Cancer Center, The Affiliated Hospital of Guangdong Medical College, Zhanjiang, China.
authors.forename: Zhong-Hua
authors.initials: ZH
authors.lastname: Yu
authors.affiliation: Department of Radiation Oncology, Fujian Provincial Tumor Hospital, Fuzhou, China.
authors.forename: Jian-Cheng
authors.initials: JC
authors.lastname: Li
authors.affiliation: Department of Radiation Oncology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China.
authors.forename: Zhi-Bin
authors.initials: ZB
authors.lastname: Cheng
authors.affiliation: Department of Radiation Oncology, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
authors.forename: Long
authors.initials: L
authors.lastname: Chen
authors.affiliation: Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
authors.forename: Xiao
authors.initials: X
authors.lastname: Hu
authors.affiliation: Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
authors.forename: Yuan-Yuan
authors.initials: YY
authors.lastname: Chen
authors.affiliation: Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
authors.forename: Jin
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of Radiation Oncology, Guangzhou General Hospital of Guangzhou Military Command, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
authors.forename: Hong-Lian
authors.initials: HL
authors.lastname: Ma
authors.affiliation: Cancer Center, The Affiliated Hospital of Guangdong Medical College, Zhanjiang, China.
authors.forename: Zu-Min
authors.initials: ZM
authors.lastname: Xu
authors.affiliation: Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
authors.forename: Ru-Biao
authors.initials: RB
authors.lastname: Lu
authors.affiliation: Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
authors.forename: Xiao-Wu
authors.initials: XW
authors.lastname: Deng
authors.affiliation: Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China. Electronic address: chenming@sysucc.org.cn.
authors.forename: Ming
authors.initials: M
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D000077143:Docetaxel; D043169:Endostatins / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011446:Prospective Studies; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D043169:Endostatins; D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin
keywords: Angiogenesis inhibitor; Chemotherapy; Endostatin; Lung cancer; Radiotherapy